Talk:Ketamine: Difference between revisions

Line 9:

Intravenous infusion in research labs has produced a very high correlation between blood levels and psychedelic effects.<ref>[Ketamine: Dreams and Realities, p73]</ref> The intravenous administration of 50 - 100 mg of ketamine can reproduce all of the features which have commonly been associated with [[Near-death experience|NDE]]'s. Intramuscular administration also results in NDE's, but events evolve at a slower pace and are longer lasting (Domino et al., 1965; Rumpf ,1969; Collier, 1972; Siegel,1978, 1980,1981; Stafford, 1977; Lilly, 1978; Grinspoon and Bakalar, 1981; White, 1982; Ghoniem et al., 1985; Sputz, 1989; Jansen, 1989a,b, 1990b, 1993, 1995, 1996).<ref>http://www.near-death.com/experiences/lsd03.html</ref>

The typical intravenous antidepressant dosage of ketamine used to treat depression is low and results in maximal plasma concentrations of 70 to 200 ng/mL (294–841 nM).<ref name="pmid28249076">{{cite journal | vauthors = Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB | title = A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders | journal = JAMA Psychiatry | volume = 74 | issue = 4 | pages = 399–405 | year = 2017 | pmid = 28249076 | doi = 10.1001/jamapsychiatry.2017.0080 | url = }}</ref>

Revision as of 03:06, 15 October 2017 view source >David Hedlund medical settings ← Older edit		Revision as of 03:19, 15 October 2017 view source >David Hedlund antidepressant Newer edit →
Line 9:		Line 9:

	Intravenous infusion in research labs has produced a very high correlation between blood levels and psychedelic effects.<ref>[Ketamine: Dreams and Realities, p73]</ref> The intravenous administration of 50 - 100 mg of ketamine can reproduce all of the features which have commonly been associated with [[Near-death experience\|NDE]]'s. Intramuscular administration also results in NDE's, but events evolve at a slower pace and are longer lasting (Domino et al., 1965; Rumpf ,1969; Collier, 1972; Siegel,1978, 1980,1981; Stafford, 1977; Lilly, 1978; Grinspoon and Bakalar, 1981; White, 1982; Ghoniem et al., 1985; Sputz, 1989; Jansen, 1989a,b, 1990b, 1993, 1995, 1996).<ref>http://www.near-death.com/experiences/lsd03.html</ref>		Intravenous infusion in research labs has produced a very high correlation between blood levels and psychedelic effects.<ref>[Ketamine: Dreams and Realities, p73]</ref> The intravenous administration of 50 - 100 mg of ketamine can reproduce all of the features which have commonly been associated with [[Near-death experience\|NDE]]'s. Intramuscular administration also results in NDE's, but events evolve at a slower pace and are longer lasting (Domino et al., 1965; Rumpf ,1969; Collier, 1972; Siegel,1978, 1980,1981; Stafford, 1977; Lilly, 1978; Grinspoon and Bakalar, 1981; White, 1982; Ghoniem et al., 1985; Sputz, 1989; Jansen, 1989a,b, 1990b, 1993, 1995, 1996).<ref>http://www.near-death.com/experiences/lsd03.html</ref>

			The typical intravenous antidepressant dosage of ketamine used to treat depression is low and results in maximal plasma concentrations of 70 to 200 ng/mL (294–841 nM).<ref name="pmid28249076">{{cite journal \| vauthors = Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB \| title = A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders \| journal = JAMA Psychiatry \| volume = 74 \| issue = 4 \| pages = 399–405 \| year = 2017 \| pmid = 28249076 \| doi = 10.1001/jamapsychiatry.2017.0080 \| url = }}</ref>